Amendments to the Claims:

Please cancel claim 23 and amend claim 1 as follows.

- 1. (Currently Amended) A method for stably transferring DNA into multi-potential hematopoietic stem cells in the GO phase of the cell cycle, which comprises transducing said multi-potential hematopoietic stem cells with an adeno-associated virus vector that contains said DNA, wherein the transferred DNA remains integrated into the genome of the multi-potential hematopoietic stem cells for at least 4 weeks, wherein the multi-potential hematopoietic stem cells are maintained in the presence of cytokines IL-3, IL-6 and stem cell factor, and wherein the levels of said cytokines are about 10 ng/ml IL-3, about 10 ng/ml IL-6 and about 1 ng/ml stem cell factor.
- 2. (Previously Presented) A method according to claim 1, wherein the transduced multi-potential hematopoietic stem cells are maintained under conditions such that at least about 92 to 99% of the cells in the GO phase remain in the GO phase for at least about two days.
- 3. (Original) A method according to claim 2, wherein the conditions under which the transduced multi-potential hematopoietic stem cells are maintained include a transduction time of about 2 hours to about 48 hours.
- 4. (Original) A method according to claim 2, wherein the conditions under which the transduced multi-potential

hematopoietic stem cells are maintained include a transduction time of about 2 hours to about 24 hours.

- 5. (Original) A method according to claim 2, wherein the conditions under which the transduced multi-potential hematopoietic stem cells are maintained include a transduction time of about 18 hours to about 24 hours.
- 6-12. (Canceled).
- 13. (Previously Presented) A method according to claim 1, wherein the transferred gene remains integrated into the genome of the multi-potential hematopoietic stem cells for at least 8 weeks.
- 14. (Original) A method according to claim 1, wherein the multipotential hematopoietic stem cells are CD34***CD38° cells.
- 15. (Original) A method according to claim 1, wherein the adeno-associated virus vector contains said DNA within the adeno-associated virus inverted terminal repeats, and wherein the adeno-associated virus vector is encapsidated.
- 16. (Canceled).
- 17. (Original) A method according to claim 15, wherein the adeno-associated virus vector has a wild-type polyadenylation region.

- 18. (Original) A method according to claim 15, wherein the adeno-associated virus vector has a heterologous polyadenylation region.
- 19-21. (Canceled).

49 (

- 22. (Original) A method according to claim 1, wherein the DNA is selected from a gene, a gene fragment, an antisense DNA, a marker gene, a reporter gene and a recombinant DNA.
- 23. (Canceled).
- 24-33. (Canceled).